

PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

<https://marketpublishers.com/r/PECEF2FA13EEN.html>

Date: November 2017

Pages: 311

Price: US\$ 3,250.00 (Single User License)

ID: PECEF2FA13EEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under PD-1 and PD-L1 Inhibitors.

This Report provides comprehensive insights across PD-1 and PD-L1 Inhibitors including detailed Marketed product profiles. The report has information on detailed pipeline portfolio including Phase III, Phase II, Phase I, Pre-Clinical and Discovery Products. With more than 50 products in various stages of development, the pipeline seems encouraging which has made PD-1 and PD-L1 the most talked about Immunology target.

There are 50+products in pipeline and 5 products have been marketed so far. The focus is majorly on the antibody-based interventions targeting programmed cell death protein 1 (PD-1) on T lymphocytes and its principal ligand (PD-L1) on tumor cells to restore latent anti-tumor immunity.

KEY COVERAGE AND BENEFITS:

1. In-depth analysis of the 50+ pipeline assets.
2. Pipeline landscape provides a deep dive into clinical, pre-clinical and discovery molecules.
3. Extensive coverage of Technology implemented by companies in this space.

4. Licensing and Deals related to PD-1 and PD-L1 inhibitors are also covered.
5. Insights on marketed products including detailed marketed product profiles. Also includes Historical and Five years forecasted sales for Marketed products (Opdivo, Keytruda, Tecentriq, Bavencio and Imfinzi).
6. Extensive coverage of ASCO 2017 updates and related insights.
7. Therapeutic assessment by molecule type, route of administration, monotherapy and combination products.
8. Detailed information on inactive projects in the pipeline for PD-1 & PD-L1 Inhibitors.
9. Information to identify emerging players with potentially lucrative products.

Contents

- Executive Summary
- Technology
- Product Type by Specificity
- ASCO 2017 Highlights
- Programmed Death 1 (PD-1)
- Programmed Death Ligand 1 (PD-L1)
- Role of PD-1 and PD-L1 pathways
- MOA of PD-1 and PD-L1 inhibitors
- Significance of PD-1 and PD-L1 inhibitors
- PD-1 and PD-L1 Active Therapy Areas & Epidemiology
- Biomarkers - PD-1 and PD-L1 inhibitors
- Major issues with PD-L1 as a Biomarker
- Market Overview
- Comparative Analysis of Pipeline & Marketed Products
- Marketed Drug Candidate Profiles
- ASCO 2017 Updates
- Pipeline Therapeutics
- Comparative Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Late Stage(Phase III) ProductProfiles
- Mid Stage Products (Phase II)
- Comparative Analysis
- Mid Stage(Phase II) ProductProfiles
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Early Stage(Phase I and IND) Product Profiles
- Pre-clinical and Discovery Stage Products
- Comparative Analysis
- Pre-clinical and Discovery Stage Product Profiles
- Therapeutic Assessment: Active Products
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dormant Products

Comparative Analysis
Appendix

List Of Tables

LIST OF TABLES

Table 1: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors

Table 2: Total Drugs for PD-1 and PD-L1 Inhibitors

Table 3: Late Stage Products (Phase III)

Table 4: Mid Stage Products (Phase II)

Table 5: Early Stage Products (Phase I and IND)

Table 6: Pre-clinical and Discovery Stage Products

Table 7: Assessment by Monotherapy Products

Table 8: Assessment by Combination Products

Table 9: Assessment by Route of Administration

Table 10: Assessment by Stage and Route of Administration

Table 11: Assessment by Molecule Type

Table 12: Assessment by Stage and Molecule Type

Table 13: Dormant Products

List Of Figures

LIST OF FIGURES

- Figure 1: Illustration: T cell interaction with cancer
- Figure 2: Illustration: PD-L1/PD-1 Pathway
- Figure 3: Illustration: MOA of PD-1 and PD-L1
- Figure 4: Marketed and Pipeline products for PD-1 and PD-L1 Inhibitors
- Figure 5: Total Drugs for PD-1 and PD-L1 Inhibitors
- Figure 6: Late Stage Products (Phase III)
- Figure 7: Mid Stage Products (Phase II)
- Figure 8: Early Stage Products (Phase I)
- Figure 9: Pre-clinical Stage and Discovery Products
- Figure 10: Assessment by Monotherapy Products
- Figure 11: Assessment by Route of Administration
- Figure 12: Assessment by Stage and Route of Administration
- Figure 13: Assessment by Molecule Type
- Figure 14: Assessment by Stage and Molecule Type
- Figure 15: Dormant Products

I would like to order

Product name: PD-1 and PD-L1 Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2017

Product link: <https://marketpublishers.com/r/PECEF2FA13EEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PECEF2FA13EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970